[1]邓森灵,兰代群,曹雅文,等.上皮性卵巢癌患者血清miR-362 和miR-485 的表达水平及其与预后的相关性研究[J].现代检验医学杂志,2022,37(04):35-37+42.[doi:10.3969/j.issn.1671-7414.2022.04.007]
　DENG Sen-ling,LAN Dai-qun,CAO Ya-wen,et al.Expression of miR-362 and miR -485 in Serum of Patients with Epithelial Ovarian Cancer and Their Correlation with Prognosis[J].Journal of Modern Laboratory Medicine,2022,37(04):35-37+42.[doi:10.3969/j.issn.1671-7414.2022.04.007]
点击复制

上皮性卵巢癌患者血清miR-362 和miR-485 的表达水平及其与预后的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年04期
页码:
35-37+42
栏目:
论著
出版日期:
2022-07-15

文章信息/Info

Title:
Expression of miR-362 and miR -485 in Serum of Patients with Epithelial Ovarian Cancer and Their Correlation with Prognosis
文章编号:
1671-7414（2022）04-035-04
作者:
邓森灵; 兰代群; 曹雅文; 符春丽; 韩雪茹; 苏红娥; 闫志强
海南西部中心医院妇产科，海南那大571799
Author(s):
DENG Sen-ling;  LAN Dai-qun;  CAO Ya-wen;  FU Chun-li;  HAN Xue-ru;  SU Hong-e; YAN Zhi-qiang
Department of Obstetrics and Gynecology，Central Hospital of Western Hainan，Hainan Nada 571799， China
关键词:
上皮性卵巢癌; 微小核糖核酸-362; 微小核糖核酸-485; 临床病理特征
分类号:
R737.31；R730.43
DOI:
10.3969/j.issn.1671-7414.2022.04.007
文献标志码:
A
摘要:
目的 探讨血清微小核糖核酸-362（miR-362）及微小核糖核酸-485（miR-485）在上皮性卵巢癌（epithelialovarian cancer, EOC）患者中的表达及其与预后的相关性。方法 选取2017 年1 月～ 2020 年3 月海南西部中心医院收治的EOC 患者98 例和正常对照组50 例，检测两组血清miR-362 和miR-485 表达水平。应用Kaplan-Meier 法绘制生存曲线，采用单因素及多因素COX 回归模型分析影响EOC 患者预后不良的危险因素。结果 EOC 组血清miR-362（0.42±0.05）及miR-485（0.51±0.08）表达水平明显低于对照组（2.37±0.96，1.74±0.62），差异有统计学意义（t=17.913,14.520，均P ＜ 0.001）。Kaplan-Meier 分析显示，miR-362 及miR-485 低表达与EOC 患者总生存率有关（χ2=14.518,12.610，均P ＜ 0.001）。多因素COX 回归分析显示，临床分期[HR（95%CI）=1.904（1.327 ～ 3.185）]、淋巴结转移[HR（95%CI）=1.953（1.401 ～ 3.394）]、腹膜转移[HR（95%CI）=3.450（2.617 ～ 7.105）]、miR-362 ＜ 1.30[HR（95%CI）=2.755（2.104 ～ 6.118）] 及miR-485 ＜ 1.05[HR（95%CI）=2.106（1.513 ～ 4.782）] 是影响EOC 患者预后不良的独立危险因素（均P ＜ 0.05）。结论 EOC 患者血清miR-362 及miR-485 表达水平明显下调，其低表达与EOC 患者总生存率有关，可作为EOC 预后评估的生物学指标。
Abstract:
Objective To investigate the expression of miR-362 and miR-485 in epithelial ovarian cancer (EOC) patients and its correlation with prognosis. Methods The 98 cases of EOC patients and 50 cases of normal control group admitted to Central Hospital of Western Hainan from January 2017 to March 2020 were selected. The expression levels of miR-362 and miR-485 in serum of the two groups were detected. Kaplan-Meier method was used to draw survival curve, single factor and multivariate COX regression models were used to analyze the risk factors of poor prognosis in EOC patients. Results The expression levels of serum miR-362 (0.42±0.05) and miR-485 (0.51±0.08) in EOC group were significantly lower than those in control group(2.37±0.96，1.74±0.62)，the differences were statistically significant（t=17.913,14.520，all P ＜ 0.001）. Kaplan-Meier analysis showed that the low expression of serum miR-362 and miR-485 were related to the overall survival of EOC patients（ χ2=14.518, 12.610， all P＜0.001）. Multivariate COX regression analysis showed that clinical stage [HR (95%CI) =1.904 (1.327～3.185)], lymph node metastasis[HR (95%CI)=1.953 (1.401～3.394)], peritoneal metastasis [HR (95%CI)=3.450 (2.617 ～ 7.105)], miR-362<1.30 [HR (95%CI)=2.755 (2.104 ～ 6.118)] and miR-485<1.05 [HR (95%CI)=2.106 (1.513 ～ 4.782)] were the prognostic factors affecting EOC independent risk factors（P<0.05）. Conclusion The expression levels of serum miR-362 and miR-485 in patients with EOC were significantly down-regulated, and their low expression levels were associated with overal survival in patients with gastric cancer, which can be used as biological indicators for prognosis evaluation of EOC.

参考文献/References:

[1] GAONA-LUVIANO P, MEDINA-GAONA L A,MAGA?A-P?REZ K. Epidemiology of ovarian cancer[J]. Chinese Clinical Oncology, 2020, 9(4): 47.
[2] PARIZADEH S M, JAFARZADEH-ESFEHANI R,GHANDEHARI M, et al. Circulating and tissue microRNAs as biomarkers for ovarian cancer prognosis[ J]. Current Drug Targets, 2019, 20(14): 1447-1460.
[3] 苏英杰, 高晨曦, 张颐.MicroRNA 在卵巢癌诊疗中的作用[J]. 肿瘤学杂志, 2021,27 (1): 4-8. SU Yingjie, GAO Chenxi, ZHANG Yi. Research progress on microRNA in diagnosis and treatment of ovarian cancer [J]. Journal of Chinese Oncology,2021,27 (1): 4-8.
[4] YANG Shuya, SUN Yuanjie, JIANG Dongbo, et al.MiR-362 suppresses cervical cancer progression via directly targeting BAP31 and activating TGFβ/Smad pathway [J]. Cancer Medicine, 2021, 10(1): 305-316.
[5] WU Shanshan, LIU Shimei, SONG Huaihua, et al.Circular RNA HIPK3 plays a carcinogenic role in cervical cancer progression via regulating miR-485-3p/FGF2 axis [J]. Journal of Investigative Medicine, 2021,69(3): 768-774.
[6] 中国抗癌协会妇科肿瘤专业委员会. 卵巢恶性肿瘤诊断与治疗指南( 第四版)[J]. 中国实用妇科与产科杂志, 2018, 34 (7): 739-749. Gynecological Tumor Committee of Chinese Anticancer Society. Guidelines to the diagnosis and treatment of malignant ovary tumors(4th edition) [J]. Chinese Journal of Practical Gynecology and Obstetrics, 2018,34 (7): 739-749.
[7] NGUYEN V, YUE Chenyang, DU K Y, et al. The role of microRNAs in epithelial ovarian cancer metastasis[J]. International Journal of Molecular Sciences, 2020, 21(19): 7093.
[8] Z?VESK? L, JAND?KOV? E, WEINBERGER V, et al. Ovarian cancer: Differentially expressed microRNAs in tumor tissue and cell-free ascitic fluid as potential novel biomarkers[J]. Cancer Investigation, 2019, 37(9):440-452.
[9] YANG Shuya, ZHANG Xiyang, SUN Yuanjie, et al.MicroRNA-362-3p inhibits migration and invasion via targeting BCAP31 in cervical cancer[J]. Frontiers in Molecular Biosciences, 2020, 7: 107.
[10] DAI Yuanyuan, XIE Fengyan, CHEN Yan. Reduced levels of miR-485-5p in HPV-infected cervical cancer promote cell proliferation and enhance invasion ability[J]. FEBS Open Bio, 2020, 10(7): 1348-1361.
[11] YUAN Jialing, LI Tao, YI Ke, et al. The suppressive role of miR-362-3p in epithelial ovarian cancer[J].Heliyon, 2020, 6(7): e04258.
[12] YANG Y, LIU J, QIAN X, et al. MiR-485-5p improves the progression of ovarian cancer by targeting SRC in vitro and in vivo[J]. Neoplasma, 2020, 67(5): 1022-1031.
[13] CAO Shujun, LI Na, LIAO Xihong. MiR-362-3p acts as a tumor suppressor by targeting SERBP1 in ovarian cancer[J]. Journal of Ovarian Research, 2021, 14(1):23.
[14] ZHOU Q H, ZHAO Y M, JIA L L ,et al. MiR-595 is a significant indicator of poor patient prognosis in epithelial ovarian cancer[J]. European Review for Medical and Pharmacological Sciences, 2017, 21(19):4278-4282.
[15] PRAHM K P, H?GDALL C, KARLSEN M, et al.Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer[J].PLoS One, 2018, 13(11): e0207319.

相似文献/References:

[1]林燕玲,王　瑛,张　敏,等.上皮性卵巢癌组织中miR-506-3p及miR-532-5p的表达与临床病理特征及预后的相关研究[J].现代检验医学杂志,2022,37(03):83.[doi:10.3969/j.issn.1671-7414.2022.03.017]
　LIN Yan-ling,WANG Ying,ZHANG Min,et al.Correlation between the Expression of miR-506-3p and miR-532-5p and Clinicopathological Features and Prognosis in Epithelial Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2022,37(04):83.[doi:10.3969/j.issn.1671-7414.2022.03.017]
[2]李 苗,龚 姗,金海红,等.上皮性卵巢癌组织CDCA7 表达水平及其与患者预后的相关性研究[J].现代检验医学杂志,2023,38(02):118.[doi:10.3969/j.issn.1671-7414.2023.02.022 ]
　LI Miao,GONG Shan,JIN Hai-hong,et al.Expression Level of CDCA7 in Epithelial Ovarian Cancer Tissues and Its Correlation with Prognosis of Patients[J].Journal of Modern Laboratory Medicine,2023,38(04):118.[doi:10.3969/j.issn.1671-7414.2023.02.022 ]

备注/Memo

备注/Memo:
基金项目：海南省医药卫生科研基金项目(17A500318)。
作者简介：邓森灵（1986-），女，本科，主治医师，主要从事临床妇产科疾病研究，E-mail: senling2019@163.com。
更新日期/Last Update: 1900-01-01